Role of IgE cells in the exacerbation and management of asthma: An experimental study

Table 1 Baseline characteristics of participants, n (%)/mean ± SD

Characteristic	Group A (n = 100)	Group B (n = 100)	P value
Age (years)	39.6 ± 12.4	38.9 ± 11.8	0.74
Female	58 (58)	55 (55)	0.68
Duration of asthma (years)	7.1 ± 4.3	7.3 ± 4.0	0.81
Baseline IgE (IU/mL)	239.1 ± 49.7	240.6 ± 52.1	0.89
FEV1 (L)	1.91 ± 0.52	1.93 ± 0.49	0.84
ACT score	14.3 ± 2.6	14.2 ± 2.4	0.92

FEV1: Forced expiratory volume in one second; ACT: Asthma control test.

Table 2 Changes in key outcomes after 12 months

Outcome	Group A (standard therapy)	Group B (Anti-IgE + Standard)	P value
IgE reduction (%)	4.5	40.0	< 0.001
FEV1 improvement (%)	10.2	25.1	0.003
ACT score increase (points)	+3	+6	0.004
Exacerbation frequency change	-28	-65	0.001

FEV1: Forced expiratory volume in one second; ACT: Asthma control test.